Belite Bio (BLTE) news
Recent news
Belite Bio - U.S. NDA for tinlarebant accepted with PDUFA target action date February 12, 2027
Belite Bio has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for tinlarebant, a potential treatment for Stargardt disease. The Prescription Drug User Fee Act (PDUFA) target action date for the FDA’s decision has been set for February 12, 2027…
AInvest Wire · 1d agoBelite Bio announces multi-market submission of marketing authorization applications via the access consortium pathway for tinlarebant for the treatment of Stargardt disease type 1
AInvest Wire · 1d agoCPBIO renewal of continuing connected transactions, notice of special general meeting
Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
AInvest Wire · 2d agoCPBIO renewal of continuing connected transactions, notice of special general meeting
AInvest Wire · 2d agoBelite Bio, Inc: Mizuho raises target price to $234 from $220
AInvest Wire · Sep 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.